Category: Research
Research
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) trial ...
Category: Research
Research
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) trial ...
Category: Research
Research
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) trial ...
Category: Researcher Profiles
...
Stroke, Trans Ischemic Attacks, TIA, stroke therapy, Alteplase, Tenecteplase, brain imaging, CT scans, MRI, Professor Chris Levi
...
Category: News & Articles
... thrombolytic, recombinant tissue plasminogen activator (Alteplase).
The standard clot-dissolving agent Alteplase is a proven effective treatment for acute ischaemic stroke – it ... we treat. This is because of two main reasons:
Firstly, Alteplase takes too long to dissolve the clot and this leads to more brain ...
Category: News & Articles
... I’m still here.”
* The TASTE (Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation) trial is supported by the Greater ...
Stroke, Stroke research, TASTE, Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation
New Therapies Save Stroke ...
Category: Researcher Profiles
... was superior to the standard therapy for stroke, Alteplase. He has led clinical trials in this area with very promising results ...
Category: Researcher Profiles
What are your research interests?
Category: News & Articles
... their stroke.
Of those administered the standard drug Alteplase (tPA) during the trial from 2008-2011, only 36 per cent showed ... in impressive benefits over the standard treatment with Alteplase,” study leader Associate Professor Mark Parsons from the University of Newcastle* said.
“With Alteplase we have seen a few dramatic outcomes but using a higher dosage of ...
Category: News & Articles
... used for heart attacks, over the standard stroke treatment Alteplase in a broader group of stroke victims. The study has been dubbed TASTE (Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation).
Results from the Phase II ... a day, compared with 36 per cent for those administered Alteplase.
“Using Tenecteplase we’ve seen patients severely affected by ...
